Qiagen inks deal with Mirati on cancer companion diagnostic

By LabPulse.com staff writers

May 26, 2021 -- Qiagen has announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based, KRAS companion diagnostic to identify patients with cancers that have a KRAS G12C mutation and who may benefit from treatment with Mirati's adagrasib.

The agreement initially focuses on a companion diagnostic test for nonsmall cell lung cancer and allows for further development of tests for other Mirati oncology programs. The planned companion diagnostic would expand upon Qiagen's therascreen KRAS testing portfolio. Qiagen and Mirati have previously partnered for the development of a companion diagnostic.

The therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS alterations linked to cancer. Mirati is developing adagrasib as a highly selective and potent oral, small-molecule inhibitor of KRASG12C.

Qiagen posts strong sales, earnings growth in Q1
Strong growth in both COVID-19 and non-COVID-19 product groups propelled Qiagen to a 48% increase in net sales at constant exchange rates in its first...
Qiagen, DiaSorin debut Lyme disease assay
Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin...
Qiagen secures EUA for COVID-19 test
Qiagen has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for NeuMoDx, a test that helps clinicians distinguish...
Qiagen launches automated sample processing for molecular testing
Qiagen has announced the launch of a fully automated sample processing platform for IVD applications in molecular diagnostic laboratories.
Qiagen, Inovio to partner on cervical dysplasia test
Qiagen and Inovio have announced they will develop a next-generation sequencing test for HPV-linked advanced cervical dysplasia that can be used on Illumina's...

Copyright © 2021 LabPulse.com

Last Updated ls 5/26/2021 9:45:29 AM